Tratamiento de infección crónica por virus de hepatitis C en niños, ¿perspectiva hacia la curación o lejos de la meta? / Treatment of chronic hepatitis C virus infection in children, prospect towards cure or far from the goal?

Resumen La infección por el virus de hepatitis C es un problema global de salud pública; en México aproximadamente 2 % de la población se encuentra infectada. En niños, los datos de prevalencia son variables según la edad, pero se estima que 0.1 a 2 % de los niños presenta infección crónica por virus de hepatitis C, cuya principal vía de transmisión es la perinatal. Actualmente existen antivirales de acción directa aprobados en adultos con una tasa de respuesta viral sostenida superior a 95 %; sin embargo, en niños aún son pocos los estudios que confirman su seguridad y efectividad. Aunque todavía estamos lejos de la meta, avanzamos rápidamente hacia un tratamiento óptimo de curación también para pacientes pediátricos.

Abstract Infection with hepatitis C virus is a global health problem; in Mexico, approximately 2% of the population is infected. In children, data on prevalence are variable according to the age group, but 0.1-2% of children are estimated to have chronic infection with hepatitis C virus, the main way of transmission of which is perinatal. Currently, there are direct-acting antiviral agents approved in adults that offer a sustained viral response rate higher than 95%; however, in children there are still only few studies confirming their safety and effectiveness. Although we are still far from the goal, we are rapidly advancing towards an optimal curative treatment also for pediatric patients.

Hepatitis C: evaluation of outcomes and georeferencing of cases in Santa Cruz do Sul, Brazil, between 2002 and 2015. A cross-sectional study

ABSTRACT BACKGROUND: Hepatitis C virus infection is one of the main causes of chronic liver disease, with high death rates. The aim here was to analyze case outcomes, sociodemographic and clinical characteristics and spatial distribution among patients diagnosed with hepatitis C in the city of Santa Cruz do Sul (RS), Brazil. DESIGN AND SETTING: Cross-sectional study on 200 cases of hepatitis C in Santa Cruz do Sul that were notified between 2002 and 2015. METHODS: Secondary data including sociodemographic and clinical variables and type of outcome (death, follow-up, abandonment or clinical cure) were gathered. The spatial distribution analysis on hepatitis C virus cases according to outcome was based on information regarding residential address. RESULTS: 58.5% of the patients were 41 years of age and over, 67% were males and 92.5% had the chronic form of the disease. The most frequent transmission route was illicit drug injection (29%); 15.1% of the patients presented coinfection with the human immunodeficiency virus (HIV). Regarding outcomes, 31% achieved clinical cure, 10% died and 20% abandoned follow-up. The cases studied were mainly located in regions of the city characterized by lower socioeconomic status, with high frequency of places used for drug trafficking. CONCLUSION: The population consisted of adults aged 41 years and over, mostly with chronic hepatitis C. The most common transmission routes were illicit drug injection and blood transfusions. There were high rates of HIV coinfection and abandonment of disease monitoring and predominance of cases in neighborhoods with low socioeconomic status.

Nuevos antivirales frente al VHC: actualidad y perspectivas / New direct acting antiviral for hepatitis C: future perspectives

Aproximadamente 175 millones de personas están infectadas por el virus de la hepatitis C (VHC), lo que representa un 3% de la población mundial. En ausencia de tratamiento eficaz, un 25% de los pacientes desarrollan complicaciones hepáticas tras 25 años de hepatitis crónica C. Hasta hace poco, la única opción terapéutica en estos pacientes era la combinación de interferón pegilado (peg-IFN) y ribavirina (RBV). Alcanzaban la erradicación del VHC un 30-40% de los pacientes infectados con el genotipo 1 del VHC. Recientes avances han permitido desarrollar replicones y sistemas de cultivo tisulares para el VHC. Esto ha facilitado el diseño de fármacos antivirales directos (DAA) que inhiben específicamente la replicación del VHC. Los dos primeros inhibidores de la proteasa del VHC fueron aprobados en mayo de 2011. Permiten obtener tasas de curación en el 70% de los pacientes infectados con el genotipo 1 sin experiencia previa a interferón. La respuesta es menor en pacientes con fracasos previos, excepto en los recidivantes, en los que tasa de curación es del 90%...

Approximately 175 million people worldwide are chronically infected with the hepatitis C virus (HCV), representing 3% of the total world population. In the absence of successful therapy nearly 25% of these patients will develop hepatic complications within 25 years. Until recently, the only available therapeutic option for these patients was the combination of peginterferon-a plus ribavirin. Overall it allowed achievement of eradication in only 30-40% of patients infected by HCV genotype 1. The development of HCV replicons and the chance of producing infectious viral particles in culture systems have both enabled the rational design of direct-acting antivirals (DAA) that specifically inhibit HCV replication. The first two HCV protease inhibitors were marketed in May 2011. Triple therapy has increased the response rate to 70% in HCV genotype 1 carrier naïve to interferon. Although response rates are lower in prior failures, 90% sustained virological response rates are achieved in prior relapsers...

Infección por virus de la hepatitis C en niños / Hepatitis C virus infection in children

La hepatitis C se adquiere por las vías parenteral, materno-fetal y sexual. Afecta al 3 por ciento de la población mundial. La transmisión vertical constituye la principal forma de diseminación del virus actualmente. La mayoría de los niños desarrolla enfermedad crónica asintomática; sin embargo, puede observarse progresión de la enfermedad en la edad pediátrica. Los anticuerpos contra el virus de la hepatitis C no permiten discriminar entre infección activa y resuelta. Se requiere la determinación por PCR del HCV-ARN. La combinación de peginterferón y ribavirina parece ser el tratamiento más eficaz. El desarrollo de nuevos fármacos, así como el de una vacuna, constituyen los próximos desafíos.

The modes of transmission of hepatitis C virus are parenteral, sexual and maternal-fetal. It affects 3 percent of the population worldwide. Currently, vertical infection is the main way of virus spreading. Most children are clinically asymptomatic, but progression of liver disease has been described. The positivity of antibodies against hepatitis C virus does not discriminate between active and resolved infection, so determination of serum HCV-RNA is necessary. The combination of peginterferon and ribavirin appears to be the most effective treatment. Future challenges are the development of new drugs and a vaccine.

Infecção pelo vírus da hepatite C na região Amazônica brasileira / Hepatitis C virus infection in the Amazon brazilian region

O artigo avalia informações científicas disponíveis sobre a prevalência e características clínicas da infecção pelo virus da hepatite C na Amazônia Brasileira, uma área sabidamente endêmica para infecção pelos vírus das hepatites A, B e D. Toda a informação foi obtida através de extensa revisão bibliográfica de artigos originais e de revisão e de resumos publicados em periódicos conceituados ou em eventos científicos. Na Região Amazônica, a taxa de prevalência de infecção por VHC na população geral varia de 1,1 a 2,4%. Entre doadores de sangue as taxas de prevalência variam de 0,8% a 5,9%. O Estado do Pará (Amazônia oriental) e do Acre (Amazônia ocidental) apresentam as maiores taxas, 2% e 5,9%, respectivamente. Com relação à prevalência da infecção pelo VHC em grupos de risco, observa-se alta prevalência entre hemodiálisados (48,1% - 51,9%), profissionais de saúde (3,2%), contactantes de portadores do VHC (10%) e pacientes com lichen plannus (7,5%). Existe uma predominância significativa do genótipo 1, com maior freqüência do subtipo 1b. A infecção pelo VHC é similar em homens e mulheres e a maioria dos infectados têm mais de 39 anos de idade. A principal via de infecção é a parenteral e os principais fatores de risco são transfusão sangüínea e procedimentos cirúrgicos. O VHC raramente é responsável por hepatite aguda grave nesta região. Por outro lado, de todas as hepatites crônicas, 22,6% são atribuídas ao VHC na Amazônia Ocidental e 25% na Amazônia Oriental. Na Amazônia Brasileira, a infecção pelo VHC parece ter o mesmo comportamento da infecção em outras partes do mundo.

The article evaluates available scientific information concerning the prevalence and clinical characteristics of hepatitis C virus infection in the Brazilian Amazon, a know endemic area for hepatitis A, B and D viruses infection. All the information was obtained through extensive analysis of original and review articles and abstracts published in distinguished journals or in scientific meetings. In the Amazon Region, HCV infection prevalence rate in the general population varies from 1.1 to 2.4%. Among blood donators the prevalence rate varies from 0.8 to 5.9%. Pará (Eastern Amazon) and Acre (Western Amazon) State present the highest rates, 2% and 5.9%, respectively. In respect to the HCV infection prevalence rate in the risk groups, one observates high prevalence In the Brazilian Amazon, infection by HCV seems to cope in the same way of infection in other parts of the world among the hemodialized (48.1 - 51.9%), health professionals (3.2%), HCV carriers contactants (10%) and lichen plannus patients (7.5%). There is a significant predominance of genotype 1, being sub-type 1b the most frequent. The HCV infection is similar in men and women and most of the infected are above 39 years of age. The major route of infection is parenteral and the major risk factors are blood transfusion and surgical procedures. HCV is rarely responsable for acute severe hepatitis in this region. On the other hand, of all chronic hepatitis, 22.6% are attributed to HCV in the Western Amazon and 25% in the Eastern Amazon. In the Brazilian Amazon, infection by HCV seems to cope in the same way of infection in other parts of the world.

Transmisión familiar del virus de la hepatitis C en un grupo de población chilena / Familial transmission of hepatitis C virus infection in Chilean subjects

BACKGROUND: Intravenous drug use, sexual promiscuity and a longer cohabitation period are considered risk factors for familial transmission of hepatitis C virus. The relative importance of this type of transmission is a subject of controversy. AIM: To study familial clustering of hepatitis C virus infection and its risk factors. MATERIAL AND METHODS: HCV positive patients (91 with chronic hepatitis, 88 with cirrhosis, nine with hepatic carcinoma and 29 hemophiliacs) were the index cases. HCV antibodies were measured by ELISA and the type of relationship with the index case was investigated in 317 family members. RESULTS: Positive anti HVC antibodies were detected in 12 of 243 family members of patients with chronic liver disease and in none of the family members of patients with hemophilia. Of these, five were couples of an index case with a long cohabitation period. Ten members had an index case with a severe liver disease (three with Child C cirrhosis and seven with liver carcinoma). CONCLUSIONS: Family transmission of HCV infection is uncommon in Chile. The association of severe liver disease and family transmission could be due to a higher viral load as responsible for transmission during the early periods of a long lasting disease.